

**ASX Announcement**  
**23 March 2020**

## Regeneus to be granted new key Progenza patent in U.S.

**Highlights:**

- New key patent for Progenza to be granted by the U.S Patent and Trademark Office (USPTO)
- Patent covers treatment of a broad range of inflammatory conditions, including Acute Respiratory Distress Syndrome (ARDS) which has been linked to COVID-19
- Key Progenza patents now granted across all key target markets, including US, Japan, Europe and Australia
- The patent will provide commercial rights in the United States through to 2032 and broadens the Company's IP portfolio
- Previous Progenza patents covered the treatment of pain

**Regeneus Ltd (ASX: RGS) (Regeneus or the Company)**, a clinical-stage regenerative medicine company, today announced that the U.S Patent and Trademark Office (USPTO) has issued a notice of allowance for issuance of a new key patent for the Company's lead stem cell platform technology, Progenza, in the U.S.

The new patent to be granted covers the treatment of inflammatory conditions with the combination of stem cells and secretions. This includes inflammatory conditions caused by a wide range of diseases, such as arthritis, heart disease, autoimmune conditions, respiratory diseases, asthma, Crohn's disease and other gastrointestinal diseases.

The patent to be granted for Progenza also covers Acute Respiratory Distress Syndrome (ARDS), an inflammatory lung condition identified as a cause of death among patients diagnosed with COVID-19<sup>1</sup>. ARDS is also a common cause of respiratory failure in critically ill patients. Unlike pneumonia, there is no pharmaceutical treatment for ARDS<sup>23</sup>.

"While Regeneus' focus remains on osteoarthritis and pain opportunities, this is a key patent which strengthens our intellectual property portfolio. It also opens doors to form partnerships for Progenza for other disease and indications," said Regeneus CEO and Executive Director Leo Lee".

**-ENDS-**

---

<sup>1</sup> Chen N et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020 Feb 15;395(10223):507-513. [doi:10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7).

<sup>2</sup> Matthay, Michael A et al. "Acute respiratory distress syndrome." *Nature reviews. Disease primers* vol. 5,1 18. 14 Mar. 2019, [doi:10.1038/s41572-019-0069-0](https://doi.org/10.1038/s41572-019-0069-0)

<sup>3</sup> Boyle AJ, Sweeney RM, McAuley DF. Pharmacological treatments in ARDS; a state-of-the-art update. *BMC Medicine*. BioMed Central; 2013. p. 166. [doi:10.1186/1741-7015-11-166](https://doi.org/10.1186/1741-7015-11-166)

For personal use only

## About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address unmet medical needs in human health markets with a focus on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit [www.regeneus.com.au](http://www.regeneus.com.au) for more information.

### Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd

### Investor and Media Contact

WE Communications

T: 02 9237 2805

E: [WE-AURegeneus@we-worldwide.com](mailto:WE-AURegeneus@we-worldwide.com)

For personal use only